Tag Archives: generics

What MNCs Can Learn from Generics Companies

In the last three decades, MNCs have contributed greatly to the transfer of knowledge to generic companies in areas such as technology, marketing know-how, working methods, management techniques, R&D, and branding. However, now is the time that MNCs can also learn significantly from generic companies amid the changing global industry landscape. This evolution has enabled […]
Posted in Emerging Markets, Guest Blog, Strategy | Also tagged , , , | Leave a comment

EGA Calls for Removal of Barriers to Generics in Europe

Adrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.
Posted in Europe, Events, Global, Regulatory | Also tagged , , , | Leave a comment

Europe: Whatever Happened to Faster Reimbursement for Generics?

The plan to accelerate generic pricing and reimbursement has become another tragic European casualty, writes Brussels correspondent Reflector.
Posted in Europe, Op-Ed, pricing, Regulatory | Also tagged , , , , | Leave a comment

FDA Prohibits Another Ranbaxy Facility from Producing Drugs for US Market

FDA has reported that it notified Ranbaxy Laboratories, Ltd., on Jan. 23 that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug products. The Toansa facility is now subject to certain terms of a consent decree of permanent injunction entered against Ranbaxy in January […]
Posted in FDA, Regulatory | Also tagged , , , | 1 Comment

Momenta CEO Rebuffs Teva's Copaxone Defense

Momenta Pharmaceuticals’ CEO Craig Wheeler said comments made by Teva leadership about a “purported” generic of Copaxone are “kind of humorous.” Teva’s Copaxone, a multiple sclerosis drug that earns nearly $4 billion a year, is approaching patent expiry – and possible generic competition – on May 24. Assuming FDA approves a generic version of Copaxone, […]
Posted in Biotech, FDA, IP, leadership, Legal, People, pricing, R&D, Regulatory, Strategy | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta